CLINICAL TRIALS PROFILE FOR PIFELTRO
✉ Email this page to a colleague
All Clinical Trials for pifeltro
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03886701 ↗ | Doravirine, Rifapentine and Isoniazid Interaction | Completed | Merck Sharp & Dohme Corp. | Phase 1 | 2019-04-22 | Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes that share the same metabolic pathway as antiretroviral drugs used for those living with HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral drug when co-administered with a common anti-tuberculosis regimen of drugs. |
| NCT03886701 ↗ | Doravirine, Rifapentine and Isoniazid Interaction | Completed | Walter K. Kraft | Phase 1 | 2019-04-22 | Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes that share the same metabolic pathway as antiretroviral drugs used for those living with HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral drug when co-administered with a common anti-tuberculosis regimen of drugs. |
| NCT03894124 ↗ | Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers | Completed | Imperial College London | Phase 1 | 2019-06-12 | Study to assess the pharmacokinetics of plasma doravirine once daily over 72 hours following drug intake cessation at steady-state in healthy volunteers |
| NCT03894124 ↗ | Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers | Completed | Merck Sharp & Dohme Corp. | Phase 1 | 2019-06-12 | Study to assess the pharmacokinetics of plasma doravirine once daily over 72 hours following drug intake cessation at steady-state in healthy volunteers |
| NCT03894124 ↗ | Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers | Completed | University of Liverpool | Phase 1 | 2019-06-12 | Study to assess the pharmacokinetics of plasma doravirine once daily over 72 hours following drug intake cessation at steady-state in healthy volunteers |
| NCT03894124 ↗ | Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers | Completed | Chelsea and Westminster NHS Foundation Trust | Phase 1 | 2019-06-12 | Study to assess the pharmacokinetics of plasma doravirine once daily over 72 hours following drug intake cessation at steady-state in healthy volunteers |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for pifeltro
Condition Name
| Condition Name for pifeltro | |
| Intervention | Trials |
| Human Immunodeficiency Virus | 2 |
| Drug Interaction Potentiation | 1 |
| HIV-1-infection | 1 |
| HIV-infected Participants With ESRD Undergoing Routine Hemodialysis | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for pifeltro
Trials by Country
Clinical Trial Progress for pifeltro
Clinical Trial Phase
Clinical Trial Sponsors for pifeltro
Sponsor Name
| Sponsor Name for pifeltro | |
| Sponsor | Trials |
| Merck Sharp & Dohme Corp. | 3 |
| Chelsea and Westminster NHS Foundation Trust | 2 |
| Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 1 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
